• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Nine Month Earnings Jump Could Be A Game Changer For Rovi (BME:ROVI)

    Simply Wall St·11/08/2026 18:30:08
    Listen to the news
    • Laboratorios Farmaceuticos Rovi reported nine month 2026 sales of €610.17 million and net income of €162.89 million, compared with €525.06 million and €97.77 million a year earlier.
    • The wider gap between sales and net profit compared with the prior period highlights how operating execution and cost control shaped Rovi's recent earnings profile.
    • This article will now examine how Laboratorios Farmaceuticos Rovi's investment narrative could be influenced by this nine month earnings performance.

    Compare Laboratorios Farmaceuticos Rovi's earnings story with a hand picked group of financially solid peers using the list of solid balance sheet and fundamentals (192 results).

    Laboratorios Farmaceuticos Rovi Investment Narrative Recap

    To own Laboratorios Farmaceuticos Rovi, you need to believe the shift toward higher value injectables and CDMO services can offset pressure in legacy heparin products and a heavier R&D bill. The nine month sales of €610.17 million and net income of €162.89 million support the idea that the operating model still converts revenue into healthy profit.

    The key short term swing factor remains execution in CDMO contracts, where guidance was cut earlier in 2026 after a slower prefilled syringe ramp and heparin pricing headwinds. These earnings do not remove that risk, although they help show the wider group can absorb some contract timing issues and higher development spend.

    One earlier update that still matters here is management’s decision to lift 2026 R&D expectations toward about €60 million, almost double the prior year period in the first half. That choice weighs on near term margins but aligns with Rovi’s plan to build out the ISM based portfolio beyond Okedi into assets like Letrozole SIE and Risperidone QUAR.

    When you set that against the latest nine month figures, the question becomes whether this heavier cost base is justified by future optionality in long acting injectables and incremental CDMO capacity, such as the Madrid upgrades and Phoenix acquisition. The current report gives you more data on the earnings side of that trade off but does not resolve the outcome of those projects.

    Laboratorios Farmaceuticos Rovi's current narrative ties analyst expectations for €1.0b in revenue and €229.9 million in earnings by 2029 to a projected 9.5% yearly revenue growth rate, with that profit figure representing an increase of about €44.7 million from earnings of €185.2 million today.

    Uncover why Laboratorios Farmaceuticos Rovi's fair value indicates an 8% potential upside to its current price that could narrow quickly.

    BME:ROVI 1-Year Stock Price Chart
    BME:ROVI 1-Year Stock Price Chart

    Exploring Other Perspectives

    Two fair value estimates from the Simply Wall St Community range from about €74 to roughly €110 per share, so private investors are clearly not marching in lockstep on Laboratorios Farmaceuticos Rovi. When you set those pre earnings views against risks in heparin pricing and CDMO contract timing, you see a wide field of possible earnings paths that invites you to test several alternative viewpoints before forming your own stance.

    Explore another Laboratorios Farmaceuticos Rovi fair value estimate, including one that suggests as much as 60% upside from the current price.

    Reach Your Own Conclusion

    Don't just follow the ticker. Dig into the data and build a conviction that is truly your own.

    Looking For More Investment Ideas Beyond Laboratorios Farmaceuticos Rovi?

    Once you have formed a view on Laboratorios Farmaceuticos Rovi, it can help to cross check that thinking against a wider watchlist of businesses with different risk and return profiles using the Simply Wall St Screener.